Active, Not Recruiting
Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment
NCT05627245
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +24 more
- Locations
-
- University of California Davis Comprehensive Cancer Center Sacramento, California, United States
- Yale University New Haven, Connecticut, United States
- University of Kansas Clinical Research Center Fairway, Kansas, United States
- University of Kansas Cancer Center Kansas City, Kansas, United States